Angela M. BelcherChair: W.M. Keck Professor of Energy, Massachusetts Institute of Technology Professor, Department of Biological Engineering, Materials Science and Energy, Massachusetts Institute of Technology Professor, The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
Angela M. Belcher, PhD, is a biological and materials engineer with expertise in the fields of biomaterials, biomolecular materials, organic-inorganic interfaces, and solid-waste chemistry and devices. Her primary research focus is evolving new materials for energy, electronics, the environment, and medicine. She received her BS in Creative Studies with an emphasis in biology from the University of California, Santa Barbara (UCSB). She continued her education at UCSB and earned a PhD in inorganic chemistry with Professor Galen Stucky and Professor Dan Morse (1997). Following her postdoctoral research in electrical engineering at UCSB with Professor Evelyn Hu, she joined the faculty at the University of Texas at Austin in the Department of Chemistry in 1999. Dr. Belcher joined the faculty at Massachusetts Institute of Technology (MIT) in 2002 and now holds the W.M. Keck Chair in Energy. She is on the faculty of the Department of Biological Engineering, Materials Science and Engineering and the David H. Koch Institute of Integrative Cancer Research at MIT. She teaches undergraduate students in materials sciences and engineering and biological engineering. Dr. Belcher has mentored 30 PhD students and 100s of undergraduate students. In 2002, she founded the company Cambrios Technologies, Inc., and in 2007, she founded Siluria Technologies, Inc. She has worked with thousands of K-12 students, and mentored middle school students and teachers.
Dr. Belcher won the 2013 $500,000 Lemelson-MIT Prize for her inventions and was honored as the NEIC (New England Institute of Chemists) Distinguished Chemist in 2013. In 2013, she was elected to the American Academy of Arts & Sciences. Earlier, in 2010, she received the Eni Prize for Renewable and Non-Conventional Energy. In 2009, Rolling Stone magazine listed her as one of the top 100 people changing the country. In 2007, Time magazine named her a "Hero" for her research related to climate change. In 2006, she was named 'Research Leader of the Year' by Scientific American and was awarded a 2006 Popular Mechanics Breakthrough Award. In 2005, she was named one of the '10 to Watch' by Fortune magazine for "how the world will work in the next 75 years."
Dr. Belcher is also a recipient of the MacArthur "Genius Fellow"; a Four Star General Recognition Award (US Army), Presidential Early Career Award for Science and Engineering (PECASE), Top 10 Innovators Under 40 (Fortune magazine), 2002 World Technology Award (Materials), 2002 Popular Science Brilliant Ten, 2002 Technology Review Top 100 Inventors (TR100). She is a 2001 Packard Fellow, and won the 2001 Wilson Prize in Chemistry at Harvard University and was a 2001 Alfred P. Sloan Research Fellow. In addition, she received the 2000 Beckman Young Investigator Award, the 1999 DuPont and IBM Young Investigators Awards, and the 1999 Army Research Office Young Investigators Award.
Her work has been published in many prestigious scientific journals, including Science and Nature, and has been reported in the popular press, including: Time, Fortune, The Economist, Forbes (cover), Discover, Scientific American, The Scientist, Technology Review, Rolling Stone, Elle Magazine, The New York Times, The Washington Post, Business Week, The Wall Street Journal, PBS, BBC, NPR, and NOVA.
Sangeeta N. BhatiaDirector, Laboratory for Multiscale Regenerative Technologies, Massachusetts Institute of Technology
Sangeeta N. Bhatia, MD, conducts research at the intersection of engineering, medicine, and biology to develop novel platforms for understanding, diagnosing, and treating human disease. Her 'tiny technologies' interface living cells with synthetic systems, enabling new applications in tissue regeneration, stem cell differentiation, medical diagnostics and drug delivery. She and her colleagues were the first to demonstrate that microfabrication technologies used in semiconductor manufacturing could be used to organize cells of different types to produce a tissue with emergent properties.
Dr. Bhatia's findings have produced high-throughput-capable human microlivers, which model human drug metabolism, drug-induced liver disease, and interaction with human pathogens. With these platforms, she achieved the first high-throughput models that fully replicate the life cycles of hepatitis C and liver-stage human malaria. Her group also develops nanoparticles and nanoporous materials that can be designed to assemble and communicate to diagnose and treat a variety of diseases, including cancer.
Dr. Bhatia holds a BS from Brown University; an MS in mechanical engineering from MIT; a PhD in biomedical engineering from the Massachusetts Institute of Technology (MIT); and an MD from Harvard Medical School. Currently, she directs the Laboratory for Multiscale Regenerative Technologies at MIT. She is a Howard Hughes Medical Institute Investigator and the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science at MIT. She is a member of the Institute for Medical Engineering and Science and the Koch Institute for Integrative Cancer Research at MIT, a senior member of the Broad Institute, and a biomedical engineer at Brigham & Women's Hospital. Dr. Bhatia is an elected Fellow of the Massachusetts Academy of Sciences, Biomedical Engineering Society, American Institute for Medical and Biological Engineering, and the American Society for Clinical Investigation. She has been awarded the David and Lucile Packard Fellowship given to "the nation's most promising young professors in science and engineering," the NSF CAREER Award, the Harvard Medical School Diversity Award, and the Harvard-MIT Thomas McMahon Mentoring Award, among many others.
Dr. Bhatia co-authored the first undergraduate textbook on tissue engineering and has published more than 150 manuscripts, including in Science, Cell, Nature Biotechnology, Science Translational Medicine, and PNAS, that have been cited more than 13,500 times. She and her more than 150 trainees have contributed to more than 40 issued or pending patents and launched nine biotechnology companies with close to 100 products. She is a frequent advisor to governmental organizations. A highly regarded innovator, Dr. Bhatia has spoken about the role of nanotechnology at the World Economic Forum and the Gates Grand Challenges Meeting, and in the last year alone she gave over 40 invited talks. She consults widely for academia and industry, and is a member of the Board of Scientific Advisors to the National Cancer Institute, the NIH Working Group on Diversity, and the Broad Institute Strategic Advisory Committee. Her work has been profiled broadly, such as in Scientific American and Popular Science, the Boston Globe, Economist, Forbes, PBS's NOVA scienceNOW, Planet Green, and MSNBC.
Dennis S. CharneyAnne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai President for Academic Affairs, Mount Sinai Health System
Dennis S. Charney, MD, is Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and Executive Vice President for Academic Affairs of The Mount Sinai Medical Center. He is also a world expert in the neurobiology and treatment of mood and anxiety disorders, making fundamental contributions to the understanding of the causes of human anxiety, fear, and depression and the discovery of new treatment for mood and anxiety disorders.
Since Dr. Charney was named Dean in 2004, the Icahn School of Medicine has risen to, and has maintained, its strength among the top 20 institutions in National Institutes of Health (NIH) funding. It currently ranks fifth in funding per faculty member from the NIH and other sources. With a long track record of strategic recruitments across the biomedical sciences and in genomics, computational biology, entrepreneurship, and information technology, Mount Sinai has cultivated a supercharged, Silicon Valley-like atmosphere in the academic setting. ISMMS The Icahn School of Medicine is also consistently listed among the top 20 medical schools in the country according to U.S. News & World Report, and in 2009, it received the Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.
As the sole medical school affiliation for seven hospital campuses in the new Mount Sinai Health System, the Icahn School of Medicine has one of the most expansive training and research footprints in the nation. Early in his tenure as Dean, Dr. Charney unveiled Mount Sinai's $2.25 billion strategic plan that laid the foundation for the 14 robust Research Institutes that Mount Sinai is known for today. These institutes are hubs of scientific and clinical enterprise, working together to challenge the limits of science and medicine. Within-and across-them, scientists and physicians, who themselves are members of the teaching faculty, can facilitate the development of effective treatments for the most serious medical conditions.
In the Health System, Dr. Charney is currently developing the structure for complementary Clinical Institutes that will serve as Centers of Excellence for cancer, heart disease, diabetes, HIV, pulmonary diseases, and more, with the anticipation that this architecture-compatible research and clinical institutes-will further eliminate silos and generate game-changing models in clinical excellence and standards of care. To further advance this goal, Dr. Charney also led the development of a nationally unique partnership between Mount Sinai and Rensselaer Polytechnic Institute in Troy, New York, that is designed to pool Mount Sinai's expertise in biomedical research and patient care with Rensselaer's talent in engineering, computation, and prototyping. Together, the institutions are developing the educational programs, research projects, and infrastructure needed to invent novel biomedical technologies while training a new breed of translationally focused scientists.
Dr. Charney's career began in 1981 at Yale, where, within nine years, he rose from Assistant Professor to Professor of Psychiatry, a position he held from 1990 to 2000. While there, he chaired the National Institute of Mental Health (NIMH) Board of Scientific Counselors, which advises the institute's director on intramural research programs. In 2000, NIMH recruited Dr. Charney to lead the Mood and Anxiety Disorder Research Program-one of the largest programs of its kind in the world-and the Experimental Therapeutics and Pathophysiology Branch. That year, he was also elected to the Institute of Medicine of the National Academy of Sciences. His scientific research has been honored by every major award in his field, and his work in depression has led to new hypotheses regarding the mechanisms of antidepressant drugs and discovery of new and novel therapies for treatment-resistant depression, including lithium and ketamine. The work demonstrating that ketamine is a rapidly acting antidepressant has been hailed as one of the most exciting developments in antidepressant therapy in more than half a century. More recently, his pioneering research has expanded to include the psychobiological mechanisms of human resilience to stress.
Dr. Charney's studies on human resilience have culminated in the identification of ten key resilience factors for building the strength to weather and bounce back from stress and trauma. This work is summarized in an inspiring book, Resilience: The Science of Mastering Life's Greatest Challenges, coauthored with Steven Southwick and published by Cambridge University Press in 2012.
In 2004, the Icahn School of Medicine at Mount Sinai recruited Dr. Charney as Dean of Research. In 2007, he became the Dean of the School and Executive Vice President for Academic Affairs of the Medical Center. In 2013, he was named President for Academic Affairs for the Health System.
A prolific author, Dr. Charney has written more than 700 publications, including groundbreaking scientific papers, chapters, and books. He has authored many books, including Neurobiology of Mental Illness (Oxford University Press, USA, Fourth Edition, 2013); The Peace of Mind Prescription: An Authoritative Guide to Finding the Most Effective Treatment for Anxiety and Depression (Houghton Mifflin Harcourt, 2004); The Physicians Guide to Depression and Bipolar Disorders (McGraw-Hill Professional, 2006), Resilience and Mental Health: Challenges Across the Lifespan (Cambridge University Press, 2011), and, as mentioned, Resilience: The Science of Mastering Life's Greatest Challenges, for lay audiences (Cambridge University Press, 2012).
Andrew ConradDirector, Google [x], Google Inc.
Andrew Conrad, PhD, oversees a number of "moonshot" projects at Google[x], Google's research arm, and provides overall guidance on various scientific and hardware products and research. Previously, he was Chief Scientific Officer of Laboratory Corporation of America (LapCorp). In addition, Dr. Conrad is the co-founder of the National Genetics Institute where he served as Chief Scientific Officer.
Dr. Conrad also founded the California Health and Longevity Institute (CHLI) and serves as the Chief Scientific Advisor of the North Carolina Research Campus (NCRC), an academic collaboration between Duke University, University of North Carolina and North Carolina State University. He holds a PhD in Cell Biology from the University of California, Los Angeles.
Andrew ConwayHead of Data, Project Florida
Drew Conway, PhD, is a leading expert in the application of computational methods to social and behavioral problems at large-scale. He is the Head of Data at Project Florida, and has been writing and speaking about the role of data — and the discipline of data science — in industry, government, and academia for several years.
Dr. Conway has advised and consulted companies across many industries, ranging from fledgling start-ups to Fortune 100 companies, as well as academic institutions and government agencies at all levels. He started his career in counter-terrorism as a computational social scientist in the US intelligence community.
David T. CorrAssociate Professor, Department of Biomedical Engineering, Rensselaer Polytechnic Institute
David T. Corr received his BS and MS degrees from the Department of Engineering Mechanics and Astronautics, University of Wisconsin. After working as a consultant at NASA's Jet Propulsion Laboratory, he returned to the University of Wisconsin to earn his MS in Biomedical Engineering and PhD in Mechanical Engineering. Following a one-year postdoctoral research associateship in the Medical School at the University of Wisconsin, Dr. Corr spent two years as an Alberta Ingenuity Fund Postdoctoral Fellow in muscle physiology and modeling at the Human Performance Laboratory of the University of Calgary, and two years as the Ernst & Young Fellow in Joint Injury and Arthritis Research, at the McCaig Centre, University of Calgary.
Dr. Corr joined the faculty at Rensselaer Polytechnic Institute in 2006, and is currently an Associate Professor in the Department of Biomedical Engineering. His research specializes in laser-based biofabrication techniques to engineer cellular microenvironments that direct stem cell differentiation, and developing cell-based strategies for creating musculoskeletal soft tissue replacements.
Dr. Corr's laboratory developed a new bottom-up biofabrication technique, gelatin-based laser direct write (LDW), to "print" living cells for the creation of spatially-precise cellular cultures and co-cultures. Gelatin-based LDW is a CAD/CAM cell printing technique able to target and transfer cells to a substrate, with spatial precision, and can do so while preserving stem cell pluripotency. When employed with substrates of different topology and stiffness, this enables the exploration of the influence of cellular microenvironment factors on the fate decisions of stem cells and other precursor cells. Dr. Corr's lab has further developed this technique to create and pattern 3D cellular structures including microbeads, spherical microcapsules, and tubular microstrands, for use in tissue engineering and in vitro diagnostics.
Steven M. CramerWilliam Weightman Walker Professor of Chemical and Biological Engineering, Rensselaer Polytechnic Institute
Steven Cramer, PhD is the William Weightman Walker Professor of Chemical and Biological Engineering at Rensselaer Polytechnic Institute. He is currently conducting research on several areas related to protein-surface interactions including: prediction of protein binding affinity and multiscale modeling of chromatographic systems, design of chemically selective displacers, development of efficient antibody separation systems, fundamental studies in multimodal chromatography, novel chromatographic and diode based electrophoretic lab on chip systems, protein unfolding in chromatographic systems, chemometrics for process analytical technology, multilevel automated peptide synthesis/screening system for design of affinity peptides, smart biopolymer affinity precipitation systems, hierarchical nanobio systems for bioprocessing, biophysics of protein interactions with surfaces, ligands and proteins, platformable strategies for effective removal of process HCPs, and integrated semi-continuous biomanufacturing processes.
In addition, Dr. Cramer is known worldwide for his expertise in separations in general. He is the Editor-in-Chief of the international journal Separations, Science and Technology. He was the awarded the Alan S. Michaels Award for the Recovery of Biological Products (ACS Division of Biochemical Technology). He was also awarded Rensselaer's School of Engineering Research Excellence Award, a Presidential Young Investigator award from the National Science Foundation, the Early Career Award from Rensselaer Polytechnic Institute as well as several teaching awards.
Dr. Cramer has been elected a fellow of the American Institute of Chemical Engineers, the American Chemical Society, and the American Institute for Medical and Biological Engineering. He has also chaired several prestigious meetings including two International HIC/RPC Bioseparation Conferences, the ACS Recovery of Biological Products Meeting and the Gordon Conference on Reactive Polymers. He has published more than 160 papers in peer-reviewed journals and has nine patents. Importantly, he has produced 37 PhD students who have gone on to leadership positions in the biotechnology industry and academia.
Guohao DaiAssistant Professor, Department of Biomedical Engineering, Rensselaer Polytechnic Institute
Guohap Dai, PhD, is currently an Assistant Professor at the Department of Biomedical Engineering of Rensselaer Polytechnic Institute. Dr. Dai graduated from Beijing University, China with a BA in Mechanics and a MS in Biomechanics. He received his PhD from the Harvard-MIT Division of Health Science's Medical Engineering and Medical Physics program. He then completed postdoctoral training at Harvard Medical School, and subsequently joined the faculty at Rensselaer Polytechnic Institute. Dr. Dai's education and research experiences concentrate in the field of cardiovascular biomechanics and vascular biology.
Current research in Dr. Dai's laboratory focuses on the 3-D cell printing technology for vascular tissue generation, biomechanical and biochemical regulation of arterial venous differentiation from stem cells at the tissue, cellular and molecular level. He received the Partners Research Excellence Award from Harvard Medical School, the Scientist Development Award from the American Heart Association, and the National Science Foundation Faculty Early Career Award.
Kenneth L. DavisCEO and President, Mount Sinai Health System
Kenneth L. Davis, MD, is the CEO and President of the Mount Sinai Health System in New York City, one of the largest integrated health systems in the nation. The Mount Sinai Health System is renowned for providing outstanding medical care to the diverse communities it serves, as well as for its significant global outreach. The Health System encompasses the Icahn School of Medicine at Mount Sinai and seven hospital campuses, and has a large, regional ambulatory footprint.
For the decade prior to his appointment as leader of the Health System in 2013, Dr. Davis served as President and CEO of The Mount Sinai Medical Center. Under his direction, Mount Sinai successfully launched a robust era of innovation in research, education, and clinical care. As a neurobiologist, Dr. Davis's pioneering research in Alzheimer's disease led the US Food and Drug Administration to approve three of the first four drugs on the market for the treatment of Alzheimer's disease. A member of the Institute of Medicine of the National Academy of Sciences, he has published more than 500 papers and received numerous grants and awards, including the George H. W. Bush Lifetime of Leadership Award from Yale University, where he was an undergraduate. Dr. Davis was recently named a trustee of the Aspen Institute.
Scott L. FriedmanDean for Therapeutic Discovery, Icahn School of Medicine at Mount Sinai Chief of the Division of Liver Diseases, Icahn School of Medicine at Mount Sinai
Scott L. Friedman, MD, is founding Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He performed pioneering research that isolated and characterized the hepatic stellate cell, the key cell type responsible for scar production in liver. This achievement spawned an entire field that is now realizing its translational and therapeutic potential, with new anti-fibrotic therapies for liver disease reaching clinical trials. In this capacity Dr. Friedman interacts widely with the Biotech and Pharmaceutical industries in drug discovery and development, and clinical trial design. Dr. Friedman's scientific work has been continuously funded by the National Institutes of Health since 1985; he has held many national leadership positions including President of the American Association for the Study of Liver Diseases, Senior Fulbright Fellow at the Weizmann Institute of Science, and Senior Advisory Council for the National Institute of Alcohol Abuse and Alcoholism.
Dr. Friedman has published more than 300 scientific articles, and is among the most preeminent scholars in his field worldwide. In his role as Dean for Therapeutic Discovery, Dr. Friedman oversees and coordinates a rapidly expanding and highly integrated ecosystem that is advancing education to trainees and faculty about innovation and commercialization of new discoveries, expanding the infrastructure to enable therapeutic discovery, and creating resources to accelerate the creation of new devices and technologies, in part through a major partnership with Rensselaer Polytechnic Institute.
Janice L. GabriloveJames F. Holland Professor, Medicine and Oncologic Sciences Medical Director, Cancer Institute Office of Clinical Trials
Dr. Gabrilove, the James F. Holland Professor of Medicine and Oncologic Sciences and Medical Director of the Cancer Institute Office of Clinical Trials, will direct the MSCR and the PhD in Clinical Research. Dr. Gabrilove has served as the PI (since 1999) of the NIH funded and successfully re-competed K30 Clinical Research Curriculum Award. Under her leadership, the New York State Board of Reagents approved a new Master of Science (2003) and PhD (2008) in Clinical Research. Dr. Gabrilove is a world-renowned expert on the role of hematopoietic growth factors in normal and malignant hematopoiesis and the role of these cytokines in ameliorating disease or treatment related myelosuppression. She has extensive experience in the conduct of patient oriented research and translational (T1) research, specifically involving novel drug development. She is a co-inventor and patent holder for the isolation & characterization of human granulocyte colony stimulating factor (1,2) now marketed as Neupogen and Neulasta and pioneered the clinical development of its role in hematopoietic reconsititution (3,4) and stem cell mobilization (3). She also holds a patent for arsenic trioxide formulation and along with all trans retinoic acid, developed these reagents as curative FDA approved therapeutics for the treatment of acute promyelocytic leukemia; and has developed novel therapeutic strategies more recently for CLL (5,6).
Dr. Gabrilove has served as a member of the US Food and Drug Administration's Advisory Committee on Cytokines and Biologics, the NIH Hematology-2 Study Section, The NCI Special Emphasis Panel for SPORE Reviews and has been an elected counselor and member of the Executive Committee of the American Society of Hematology, Dr Gabrilove has also been previously elected to the American Society for Clinical Investigation. She is the author or coauthor of more than 200 articles and abstracts that have been published in high impact peer-reviewed journals such as the Journal of Clinical Oncology, New England Journal of Medicine, Journal of Cell Biology, Blood and the Journal of Clinical Investigation. Dr Gabrilove has served/sits on the editorial boards of Leukemia, UptoDate, Blood, and Clinical Cancer Research.
Having previously served as the Co-Director of the Hematology-Oncology Fellowship Program at Memorial Sloan Kettering Cancer Center, Chief of the Division of Hematology-Oncology, Vice Chair for Clinical Research in the Department of Medicine at MSSM, and now as Director of the Clinical Research Education Program out of the Graduate School of Biological Sciences, Dr. Gabrilove has extensive experience and success in training and mentoring individuals for successful careers in clinical research, and has personally fostered the development of more than 30 successful academic leaders currently in junior and senior faculty positions at outstanding academic institutions including The Dana Farber, MD Anderson, Memorial Sloan Kettering Cancer Centers, MSSM and Cornell as well as renown institutions in Europe and Australia.
More recently in her capacity as Director of the Clinical Research Education Program, Dr. Gabrilove has become increasingly interested in both qualitative and patient centered outcomes research, with a particular interest in ultimately discerning the impact of cultural competency on patient centered care (7).
Annetine GelijnsEdmond A. Guggenheim Professor of Health Policy, Icahn School of Medicine at Mount Sinai
An expert in health policy and clinical evaluative research, Annetine Gelijns' cutting-edge research has provided critical insight into the forces that drive the rate and direction of technological change in medicine that promises to improve patient outcomes and reduce health care costs.
As Chair of the Department of Population Health Science and Policy and Co-Director of the International Center for Health Outcomes and Innovation Research (InCHOIR) at Mount Sinai, Dr. Gelijns' research focuses on surgical and device-based trials; comparative effectiveness research; and the factors shaping the development and diffusion of medical technology, and their policy implications. She has written extensively about the uncertainty involved in medical research, the roles of the public and private sectors in technological change, and the dynamics of medical innovation. Her more recent work has focused on the design, execution and policy implications of clinical trials of novel surgical procedures, biologicals and devices. She directed the data coordinating center (DCC) for several NIH- and industry-supported trials as well as the DCC for the NIH- and CIHR-funded Cardiothoracic Surgical Trials Network.
Dr. Gelijns served as a consultant to various national and international organizations, including the WHO, the OECD, Paris, France, the National Academy of Engineering and the Institute of Medicine, and she was a member of the board of the International Society on Technology Assessment in Health Care. She has also authored or co-authored more than 130 peer-reviewed articles, books, book chapters, editorials and reviews.
Eric J. GertlerExecutive Vice President and Managing Director, Center for Economic Transformation, New York City Economic Development Corporation
Eric J. Gertler, JD, is Executive Vice President at the New York City Economic Development Corporation and Managing Director, Center for Economic Transformation (CET) for the City of New York. The CET aims to develop New York City's major business sectors by implementing policy and programmatic initiatives that address current issues faced by each industry, create good jobs, and promote entrepreneurship and economic diversification across the five boroughs.
Prior to his role at the NYCEDC, Mr. Gertler served in leadership roles at a number of technology companies, including Altruik, PrimeAxis Media, and Privista. Prior to these initiatives, he worked in the magazine and newspaper industries, with his last position being the President of the three magazines US News & World Report, Fast Company and The Atlantic Monthly. He is also the author of the book Prying Eyes: Protect Your Privacy From People Who Sell To You, Snoop on You, or Steal From You (Random House). He is a member of Young Presidents Organization (YPO - WPO) and recently served as the Chair for the New York Metro chapter.
Myshkin IngawaleCo-Founder, Biosense
Myshkin Ingawale, PhD, co-founded Biosense, an internationally recognized med-tech company designing and building innovative, disruptive health care technologies. He has advised the team at the Inter Institutional Inclusive Innovation Center, and currently is the Chief of Staff at Xiaomi India. In the past, Dr. Ingawale has worked at McKinsey & Company on client engagements across the banking, technology, pharmaceutical and health care sectors. He has been a researcher at the Massachusetts Institute of Technology, where he was part of the team that conceptualized and built the Copenhagen Wheel, an innovative electric bicycle concept demoed at the United Nations Climate Summit 2009.
Dr. Ingawale holds a PhD in Management Information Systems from the Indian Institute of Management, Calcutta and a B.Tech degree in Electrical Engineering from the National Institute of Technology, Bhopal. His PhD research on the conditions under which quality emerges in open collaborative platforms like Wikipedia has been published in the international journal Online Information Review (OIR), and at multiple conferences. He is a regular speaker at global conferences such as TED, Global Insight Network, Autodesk University, and St. Gallen's Symposium.
Shirley Ann JacksonPresident, Rensselaer Polytechnic Institute
The Honorable Shirley Ann Jackson, PhD, is the 18th president of Rensselaer Polytechnic Institute of Troy, New York, and Hartford, Connecticut, the oldest technological research university in the United States.
Described by Time magazine as "perhaps the ultimate role model for women in science," Dr. Jackson, a theoretical physicist, has held senior leadership positions in government, industry, research, and academe.
Since 1999, Dr. Jackson has led an extraordinary transformation of Rensselaer Polytechnic Institute under an ambitious strategic effort known as The Rensselaer Plan, now updated as The Rensselaer Plan 2024. With a focus on Rensselaer as a top-tier technological research university with global reach and global impact, her tenure has been marked by a successful $1.4 billion capital campaign, the hiring of more than 300 new faculty, a tripling of research awards, a tripling of applications to the freshman class, and the construction of state-of-the art research platforms, including the Center for Biotechnology and Interdisciplinary Studies.
In 2009, President Barack Obama appointed Dr. Jackson to the President's Council of Advisors on Science and Technology (PCAST). She also serves on the White House Advanced Manufacturing Partnership Steering Committee 2.0, the US Secretary of Energy Advisory Board, and the US Secretary of State's International Security Advisory Board.
In 2012, Dr. Jackson was elected as an international fellow of the British Royal Academy of Engineering. She is member of the US National Academy of Engineering and the American Philosophical Society, and a fellow of the American Association for the Advancement of Science (AAAS). She is a past president of the AAAS and former chairman of the AAAS board of directors. She is also a fellow of the American Academy of Arts and Sciences and the American Physical Society. She is a member of the board of the World Economic Forum USA. She is Vice Chair of the Board of Regents of the Smithsonian Institution, a trustee of the Brookings Institution, and a member of the board of the Council on Foreign Relations. She is a life member of the MIT Corporation.
Dr. Jackson is a director of several major corporations, including FedEx, IBM, Marathon Oil, Medtronic, and PSEG. From 2006 to 2013, she was chairman of the board of NYSE Regulation. She is a former director of NYSE Euronext and its predecessors. She is also a former governor of the US Financial Industry Regulatory Authority.
Before taking on the leadership of Rensselaer Polytechnic Institute, Dr. Jackson served as chairman of the United States Nuclear Regulatory Commission (NRC) from 1995 to 1999, revamping the agency's regulatory approach. While at the NRC, she also spearheaded the formation of the International Nuclear Regulators Association and served as the group's first chairman.
Before leading the NRC, she was a theoretical physicist at AT&T Bell Laboratories and a professor of theoretical physics at Rutgers University, where she studied the electronic and optical properties of two-dimensional systems, and layered compounds. Dr. Jackson holds an SB in physics and a PhD in theoretical elementary particle physics from the Massachusetts Institute of Technology, as well as 52 honorary doctoral degrees.
Jeffrey M. KarpAssociate Professor, Brigham and Women's Hospital, Harvard Medical School Principal Faculty, Harvard Stem Cell Institute, Harvard University Affiliate Faculty, Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology
Jeffrey M. Karp, PhD, is an Associate Professor at Brigham and Women's Hospital, Harvard Medical School, and is Principal Faculty at the Harvard Stem Cell Institute, and affiliate faculty at Massachusetts Institute of Technology (MIT) through the Harvard-MIT Division of Health Sciences and Technology.
Dr. Karp's research uses materials and biology to solve medical problems with emphasis on nanoscale/microscale materials and bio-inspiration. He has published more than 100 peer-reviewed papers and book chapters, given more than 130 national and international invited lectures, and has 50 issued or pending patents. Several technologies that Dr. Karp invented are currently being translated into medical products to improve the quality of life of suffering patients. His work has been recognized by CNN, NPR Science Fridays, the Boston Globe, ABC News, MSNBC, Fox News, CBC Quirks and Quarks, CanadaAM, BBC, the Los Angeles Times, Forbes, National Geographic, Popular Science, the Washington Post, the New York Post, and by Wired magazine. In 2011, the Boston Business Journal recognized Dr. Karp as a "Champion in Health Care Innovation" and in 2013 the Institute for Chemical Engineers (IChemE) named one of his technologies the "Most Innovative Product of the Year." MIT Technology Review (TR35) also recognized Dr. Karp as being one of the top innovators in the world under the age of 35. He has received the Society for Biomaterials Young Investigator Award and his work has been selected as one of Popular Mechanics' "Top 20 New Biotech Breakthroughs that Will Change Medicine." Dr. Karp was also elected in 2013 to the American Institute for Medical and Biological Engineering's College of Fellows and as a Kavli Fellow.
In addition, Dr. Karp is an acclaimed mentor. He was selected as the Outstanding Faculty Undergraduate Mentor among all faculty at MIT and received the HST McMahon Mentoring Award for being the top mentor among all faculty who mentor Harvard-MIT students. To date, 16 trainees from his laboratory have secured faculty positions at institutions throughout the world.
Patricia KovatchAssociate Dean, Scientific Computing, Icahn School of Medicine at Mount Sinai
Patricia Kovatch is the founding Associate Dean for Scientific Computing at the Icahn School of Medicine at Mount Sinai. Joining in October 2011, she established a scalable and sustainable high-performance computing infrastructure, emphasizing a collaborative approach partnering computational experts with Sinai's scientists to tackle complex scientific questions to better diagnose and treat disease. In 2014, she was awarded a $2 million NIH grant to build a 5 Petabyte Omics Data Engine.
Ms. Kovatch initiated a graduate curriculum in Scientific Computing and has led the effort for a new Masters of Science in Biomedical Informatics planned for Fall 2015. Research and development activities include improving neurosurgical virtual reality simulation environments, cloud computing and markets, and a statewide consortium to accelerate data-intensive science. She also manages teams with significant data-rich research and clinical resources: the Mount Sinai Data Warehouse, Research Data Services and WTC Data Center groups. She serves on the Board of Directors for NYSERNet and for the MS program in Business Analytics at Rensselaer Polytechnic Institute.
Prior to joining Mount Sinai, Ms. Kovatch built and led the $120 million National Institute for Computational Sciences of the University of Tennessee, Knoxville, located at Oak Ridge National Laboratory. She deployed the world's third fastest machine in November 2009, a 1.17 petaflop Cray XT5 for the National Science Foundation and has published research on wide-area parallel file systems and scheduling.
Howard LevinCo-Founder, Coridea
Along with Mark Gelfand, Howard Levin, MD, co-founded Coridea, an idea generator that focuses on the integration of unexploited cardiac, respiratory, and renal physiological mechanisms into novel therapeutic solutions for clinical practice. Since its inception in 2003, Coridea has successfully launched, or its patents helped launch, companies including Ardian, CHF Solutions, eValve and Respicardia (formerly, Cardiac Concepts), which were acquired for more than $1.5 billion in total.
Dr. Levin received his MD from the Mount Sinai School of Medicine. He did his training in cardiology at the Johns Hopkins School of Medicine and was medical director of the LVAD program at Columbia prior to moving into startups. Dr. Levin also has a master's degree in Biomedical Engineering. He is the author of more than 50 peer-reviewed scientific publications with 80 issued patents, and an additional 100 published patent applications.
Deborah L. McGuinnessTetherless World Professor of Computer and Cognitive Science, Rensselaer Polytechnic Institute Founding Director of the Web Science Research Center, Renssalaer Polytechnic Institute
Deborah L. McGuinness, PhD, is the Tetherless World Professor of Computer and Cognitive Science, the founding director of the Web Science Research Center, and the co-leader of Health Informatics for the Institute for Data Exploration and Application at Rensselaer Polytechnic Institute (RPI). She is a leading authority on the semantic web and has been working in knowledge representation and reasoning environments for more than 25 years. Dr. McGuinness has been recognized as a fellow of AAAS and won AAAI's Robert S. Engelmore Award for leadership in Semantic Web research and in bridging Artificial Intelligence and eScience, significant contributions to deployed AI applications, and extensive service to the AI community.
Prior to joining RPI, Dr. McGuiness was the acting director of the Knowledge Systems, Artificial Intelligence Laboratory and Senior Research Scientist in the Computer Science Department of Stanford University. She is also widely known for her leading role in the development of the W3C Recommended Web Ontology Language (OWL) and her work on earlier description logic languages and environments. She has built and deployed numerous ontology environments and ontology-enhanced applications, including some that have been in continuous use for over a decade at AT&T and Lucent, and two that have won deployment awards for variation reduction on plant floors and interdisciplinary virtual observatories.
In addition, Dr. McGuinness has published more than 200 peer-reviewed papers and has authored granted patents in knowledge based systems, ontology environments, configuration, and search technology.
Miguel A. NicolelisDuke School of Medicine Professor in Neurosciences, Duke University Professor of Neurobiology, Biomedical Engineering, and Psychology and Neuroscience, Duke University Founder, Center for Neuroengineering, Duke University
Miguel A. Nicolelis, MD, PhD, is the Duke School of Medicine Professor of Neuroscience at Duke University, Professor of Neurobiology, Biomedical Engineering and Psychology and Neuroscience, and founder of Duke's Center for Neuroengineering. He is Founder and Scientific Director of the Edmond and Lily Safra International Institute for Neuroscience of Natal and founder of the Walk Again Project. The Walk Again Project is an international consortium of scientists and engineers, dedicated to the development of an exoskeleton device to assist severely paralyzed patients in regaining full body mobility.
Dr. Nicolelis has dedicated his career to investigating how the brains of freely behaving animals encode sensory and motor information. As a result of his studies, Dr. Nicolelis was first to propose and demonstrate that animals and human subjects can utilize their electrical brain activity to directly control neuroprosthetic devices via brain-machine interfaces (BMI).
Over the past 25 years, Dr. Nicolelis pioneered and perfected the development of a new neurophysiological method, known today as chronic, multi-site, multi-electrode recordings. Using this approach in a variety of animal species, as well in intra-operative procedures in human patients, Dr. Nicolelis launched a new field of investigation, which aims at measuring the concurrent activity and interactions of large populations of single neurons throughout the brain. Through his work, Dr. Nicolelis has discovered a series of key physiological principles that govern the operation of mammalian brain circuits. These findings have been reported in nearly 200 peer-reviewed publications in leading journals.
Dr. Nicolelis pioneering BMI studies have become extremely influential since they offer new potential therapies for patients suffering from severe levels of paralysis, Parkinson's disease, and epilepsy. Today, numerous neuroscience laboratories in the US, Europe, Asia, and Latin America have incorporated Dr. Nicolelis' experimental paradigm to study a variety of mammalian neuronal systems. Indeed, two of his books on multi-electrode recording techniques have become the most cited works in this field. His research has influenced basic and applied research in computer science, robotics, and biomedical engineering.
Benedetta PiantellaCo-Founder, T4D Lab Faculty, Interactive Telecommunications Program, New York University
Benedetta Piantella, MPS, is a designer turned humanitarian technologist. She has taught Lego robotics, worked for Arduino in Italy and Smart Design in NYC, producing interactive prototypes for high-end clients. She has founded two engineering R&D companies focused on producing sustainable solutions to humanitarian, social, and environmental challenges worldwide. In addition, she has built partnerships with organizations such as the UN, UNICEF, the Millennium Villages Project, Universities such as NYU, Columbia, and Princeton, and multiple NGOs and has designed, prototyped and deployed projects in countries such as Uganda, Kenya, and Tanzania.
Ms. Piantella was Technology Architect for the Earth Institute and the Sustainable Engineering Lab at Columbia University. She is an Open Source advocate and is currently a faculty member at New York University's Interactive Telecommunications Program where she teaches Physical Computing and Engineering for Development.
Kristjan T. RagnarssonLucy G. Moses Professor and Chairman, Department of Rehabilitation Medicine, Icahn School of Medicine at Mount Sinai
Kristjan T. Ragnarsson, MD, graduated from the University of Iceland School of Medicine in 1969 and completed a residency in Physical Medicine and Rehabilitation (PM&R) and a clinical research fellowship in Spinal Cord Injury Medicine at the New York University Medical Center, Rusk Institute of Rehabilitation Medicine in 1975. He was appointed to the faculty of the Department of Rehabilitation Medicine of NYU School of Medicine in 1976. Involved with the New York SCI Model System of Care from its inception in 1973, he served as its Director from 1981 to 1986, when he was appointed Professor and Chairman of the Department of Rehabilitation Medicine at Mount Sinai School of Medicine, a position that he has held since.
At Mount Sinai, Dr. Ragnarsson has been responsible for the growth of the Department of Rehabilitation Medicine's clinical and academic programs while serving Mount Sinai in various leadership roles, such as President of The Mount Sinai Hospital Medical Board (1995-1997) and Chair, Board of Governors of the Mount Sinai School of Medicine Faculty Practice Associates (1997-2003). His contributions to other professional organizations have included: President of the American Spinal Injury Association (1993-1995); Board Member, American Paraplegia Society (1997-1999); member of the US Department of Veterans' Affairs Scientific Merit Review Board (1984-2000); Chairman of the NIH Consensus Conference on "Rehabilitation of Persons with Traumatic Brain Injury" (1998); President, Association of Academic Physiatrists (2009-2011); President of the Foundation for PM&R (2011-Present); and Chairman, American Academy of PM&R Marketing Task Force/Committee (1995-2000).
Dr. Ragnarsson has received numerous honors and awards for his work, including: the ASIA Lifetime Achievement Award (2002), the AAPM&R Distinguished Member Award (2004) and Distinguished Service Award (2006), the ACRM Gold Key Award of Merit (2007), and the NSCIA New York Chapter Humanitarian Award (2012). Since 1991, he has consistently been named among "The Best Doctors in New York" and since 1997 among "America's Top Doctors".
Dr. Ragnarsson's expertise includes evaluation and management of persons with physical disability due to SCI, spine disorders, brain injury, limb amputations, and pain. He was the projector director for the NIDRR funded Mount Sinai SCI Model System of Care (1990-2011) and the New York Traumatic Brain Injury Model System of Care (1987-1992). He has served on the editorial boards of the Journal of Spinal Cord Medicine (1989-Present), Topics in Spinal Cord Medicine (1995-2005), Journal of Rehabilitation Research and Development (1994-2000), and been a peer reviewer for 16 different professional journals. He has conducted various research projects and been involved in the development and testing of high technology devices for persons with disability. He has served as an external reviewer and consultant for several academic PM&R departments. He has published more than 160 articles and book chapters and made numerous presentations in his field of expertise locally, nationally, and internationally.
Eric SchadtDirector, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai Chair, Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai Jean C. and James W. Crystal Professor of Genomics, Icahn School of Medicine at Mount Sinai
Eric Schadt, PhD, is Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai.
Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling, and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. He is known for calling for a shift in molecular biology toward a network-oriented view of living systems to complement the reductionist, single-gene approaches that currently dominate biology in order to more accurately model the complexity of biological systems. He has published more than 200 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer's disease.
Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his BA degree in applied mathematics and computer science from California Polytechnic State University, his MA degree in pure mathematics from University of California, Davis, and his PhD in bio-mathematics from University of California, Los Angeles (requiring PhD candidacy in molecular biology and mathematics).
Geoffrey W. SmithDirector, Mount Sinai Institute of Technology Population Health Science and Policy at the Icahn School of Medicine
Geoffrey W. Smith, JD, is the founding Director of the Mount Sinai Institute of Technology (MSIT) at the Icahn School of Medicine at Mount Sinai (ISMMS). He is also a Professor in the Department of Health Evidence and Policy at IMSSM.
Mr. Smith is a co-founder and General Partner of Ascent Biomedical Ventures, a venture capital firm focused on early-stage life sciences investments. He has been an active founder, manager, and investor in technology-based companies since 1995. He currently serves on the Board of Directors of Azevan Pharmaceuticals, Anterios, BackBeat Medical, Biomerix, Caliber Therapeutics, Coferon, TargAnox, and Vivasure Medical.
Mr. Smith is also a Visiting Scholar at Rockefeller University where he founded and directs the University's Science & Economics Program and is an adjunct faculty member at the RU Center for Clinical and Translational Science.
Mr. Smith received a BA (with honors) from Williams College and a JD from the University of Pennsylvania Law School.
Gustavo A. StolovitzkyDirector of the Translational Systems Biology and Nano-Biotechnology Program IBM Research
Dr. Gustavo Stolovitzky is a Distinguished Research Staff Member and the Director of the Translational Systems Biology and Nano-Biotechnology Program at IBM Research, and an adjunct Professor at Columbia University and at the Icahn School of Medicine at Mount Sinai. He has led many industry projects at IBM Research including the development of silicon technology based single molecule DNA sequencing methods (the DNA Transistor Project), and the use of crowd-sourcing to improve the quality of industrial research in systems biology (the IMPROVER project). Dr. Stolovitzky is also heavily involved in academic research. In 2006 he founded and since then he leads the DREAM Challenges, an effort that nucleates a community of thousands of researchers to assess the performance of systems biology methods, to foster collaborative models of research and to accelerate the solution of important translational problems. Dr. Stolovitzky is a recognized leader in the field of computational biology, where he has pioneered the use of the Wisdom of Crowds as a robust methodology for biological network inference and predictive modeling. Dr. Stolovitzky is also a co-chair of the "RECOMB/ISCB Systems and Regulatory Genomics with DREAM Challenges" conference series, which has nucleated thousands of attendees over the past 7 years. Dr. Stolovitzky has organized more than 30 scientific Challenges, published over 125 papers and patented over 20 inventions in the fields of high-throughput biological-data analysis, reverse engineering biological circuits, the mathematical modeling of biological processes and nano-biotechnology.
Dr. Stolovitzky joined IBM Research in 1998. Previously he was a postdoctoral researcher at the Center for Studies in Physics and Biology at The Rockefeller University. He received his PhD in Mechanical Engineering from Yale University (1994) and his M.Sc. in Physics, from the University of Buenos Aires (1987). Dr. Stolovitzky has received Yale University's Henry Prentiss Becton Prize award (1994), the HENAAC's Pioneer Award for Great Minds in STEM (2013), the World Technology Awards (2013), and was distinguished as a Master Inventor in IBM Research (2013). Dr. Stolovitzky has been elected Fellow of the NY Academy of Sciences, Fellow of the World Technology Network, Fellow of the American Physical Society and Fellow of the American Association for the Advancement of Sciences.
Jan SumerelVice President, Research and Development, MakerBot
Jan Sumerel, PhD, received her doctorate in Biochemistry and Biophysics from the University of North Carolina, where she elucidated the role of cyclin proteins involved in DNA synthesis during embryogenesis. She did her postdoctoral work at the University of California at Santa Barbara, where she worked on structure directed synthesis of metal oxides and metallic materials using biomaterials.
Since her postdoctoral work, Dr. Sumerel has worked in the manufacturing of print heads for drop-on-demand printing using photostructurable glass. She helped pioneer the field of drop-on-demand printing of functional materials, impacting fields in organic electronics, printed electronics, and high throughput of biomaterial fluid deposition. Dr. Sumerel's present position is at MakerBot, where she is the Vice President of Research and Development, focusing on 3D printing of polymers and other advanced materials.
Jay M. TenenbaumFounder and Chairman, Cancer Commons
Jay (Marty) Tenenbaum, PhD, is the Founder and Chairman of Cancer Commons, a non-profit network of cancer patients, physicians, and scientists dedicated to improving outcomes through precision oncology. Its mission is to ensure that patients are treated in accord with the latest knowledge, and to continually update that knowledge based on each patient's response.
Dr. Tenenbaum brings to Cancer Commons the unique perspective of a computer scientist, Internet commerce pioneer, and cancer survivor. He was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), secure Web transaction (1993), and Internet auction (1993). In 1994, he founded CommerceNet, a global consortium, to accelerate business use of the Internet. In 1997, he co-founded Veo Systems, the company that pioneered the use of XML for automating business-to-business transactions. Dr. Tenenbaum joined Commerce One in January 1999, when it acquired Veo Systems. As Chief Scientist, he was instrumental in shaping the company's business and technology strategies. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions, which was sold to IBM in 2006, and Medstory, which was sold to Microsoft in 2007. Dr. Tenenbaum was also the Founder and Chairman of CollabRx, a provider of web-based applications and services that help cancer patients and their physicians select optimal treatments and trials (NASD: CLRX).
Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger, Ltd. He is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of CommerceNet, Efficient Finance, Patients Like Me, and the Public Library of Science. His work on behalf of melanoma patients has been honored with the Melanoma Research Foundation's Legends for a Cure Humanitarian Award and the Society for Melanoma Research's Advocate for Progress Award. He holds BS and MS degrees in Electrical Engineering from Massachusetts Institute of Technology, and a PhD from Stanford University.
Eric J. TopolDirector, Scripps Translational Science Institute Chief Academic Officer, Scripps Health Professor of Genomics, The Scripps Research Institute
Voted the "Most Influential Physician Executive" in the United States in 2012 in a national poll conducted by Modern Healthcare, Eric Topol, MD, works on genomic and wireless digital innovative technologies to reshape the future of medicine. He is a practicing cardiologist at Scripps in La Jolla, California and widely credited for leading the Cleveland Clinic to become the No.1 center for heart care. While there, he also started a new medical school, led many worldwide clinical trials to advance care for patients with heart disease, and spearheaded the discovery of multiple genes that increase susceptibility for heart attacks.
Since 2006, Dr. Topol has led the flagship NIH supported Scripps Translational Science in La Jolla. He also serves as Professor of Genomics at The Scripps Research Institute and Chief Academic Officer of Scripps Health. He pioneered the development of many medications that are routinely used in medical practice including t-PA, Plavix, Angiomax, and ReoPro and was the first physician to raise safety concerns on Vioxx.
Dr. Topol has published more than 1,100 peer-reviewed articles and more than 30 medical textbooks. In 2009, along with Francis Collins and Harold Varmus, he was selected to be one of the country's 12 "Rock Stars of Science" in GQ magazine. In 2011, the University of Michigan, where he had served on the faculty, initiated the Eric Topol Professor of Cardiovascular Medicine to recognize his contributions. The University of Rochester, his alma mater medical school, awarded him the Hutchinson Medal, the University's highest honor. Elected to the Institute of Medicine of the National Academy of Sciences, he is one of the top 10 most cited researchers in medicine. His book, The Creative Destruction of Medicine (Basic Books), was published in 2012 and has been the #1 bestseller in biotechnology, medical informatics, and medical practice on Amazon. He additionally took on the Editor-in-Chief position at Medscape in 2013 and the role of AT&T's Chief Medical Advisor in 2014. His new book on democratizing medicine will be out in early 2015.
Gordana Vunjak-NovakovicMikati Foundation Professor of Biomedical Engineering, Columbia University Professor of Medical Sciences, Columbia University
Gordana Vunjak-Novakovic, PhD, is the Mikati Foundation Professor of Biomedical Engineering and a Professor of Medical Sciences at Columbia University. She directs the Laboratory for Stem Cells and Tissue Engineering that is a home to the Bioreactor Core of the NIH Tissue Engineering Resource Center. In addition, she is the lead for bioengineering at Columbia Stem Cell Initiative and a scientific director of the Columbia University Stem Cell Core. She obtained a PhD in chemical engineering at the University of Belgrade in Serbia, and was a Fulbright Fellow at Massachusetts Institute of Technology (MIT).
The focus of her research is on engineering functional human tissues for regenerative medicine and studies of the development and disease. Dr. Vunjak-Novakovic has published three books, more than 300 journal articles, and has 68 licensed, issued or pending patents. In addition to having given more than 300 invited lectures, she has been a frequent advisor to government and industry, a study section chair, and distinguished editor for NIH, a reviewer of more than 70 scientific foundations around the world and more than 150 scientific journals.
Dr. Vunjak-Novakovic serves on the editorial boards of 23 scientific journals, on the Tissue Engineering and Regenerative Medicine Council, on the Board of Directors of the Center for Advancement of Science in Space (CASIS), and Advisory Boards of the Sloan-Kettering Center for Stem-Cell Biology, New York Stem Cell Foundation, City College of New York, Advanced Cell Technology, Organovo, and several other academic departments and companies. She also is a founder of two biotech companies.
In 2000, Dr. Vunjak-Novakovic was elected Fellow of the American Institute for Medical and Biological Engineering. In 2007, she gave the Director's lecture at the NIH, as the first women engineer to receive this distinction. In 2008, she was inducted into the Women in Technology International Hall of Fame "for developing biological substitutes to restore, maintain or improve tissue function." In 2009, she was elected to the New York Academy of Sciences. In 2010, she received the Clemson Award of the Biomaterials Society "for significant contributions to the literature on biomaterials." She is a member of the College of Fellows of the Biomedical Engineering Society. In 2012, she was elected to Academia Europaea for contributions to translational research, and to the Serbian Academy of Sciences and Arts for contributions to biology and chemistry. In 2012, she also was elected to the National Academy of Engineering "for bioreactor systems and modeling approaches for tissue engineering and regenerative medicine," as the first woman at Columbia University to receive this highest recognition. In 2013, she was elected to the Founding Class of the International Fellows of Tissue Engineering and Regenerative Medicine and to the Executive Committee of the Section for Bioengineering, National Academy of Engineering.
Jun WangDirector, BGI
Jun Wang, PhD, is the Director of the BGI (previously known as the Beijing Genomics Institute). Dr. Wang was instrumental in the 1999 founding and the growth of the BGI Bioinformatics Department, which is now widely recognized as one of world's premier research facilities committed to excellence in genome sciences. He also holds a position as an Ole RÝmer professor at the University of Copenhagen.
Dr. Wang's research focuses on genomics and related bioinformatics analysis of complex diseases and agricultural crops, with the goal of developing applications using the genomic information. He has authored more than 200 peer-reviewed original papers, of which more than 100 have been published in Cell, Nature (including Nature series), New England Journal of Medicine, and Science (26 as cover story).
Dr. Wang has received numerous awards and recognitions for his work including an award from His Royal Highness Prince Foundation, "Fortune's 40 under 40" from Fortune magazine (2013), Nature's "10 - The Year in Science" (2012); "The Hottest Scientific Researchers of 2012" (by Thomson Reuters), Lundbeck Talent Price, and Outstanding Science and Technology Achievement from the Chinese Academy of Sciences. He has also received the ZhouGuangZhao Award, TanJiaZeng Life Science Innovation Award, Top 10 Scientific Achievements In China, Major Award from Shenzhen Municipal Government, the first "TopSUN" Scientific Paper Award from Peking University, Tan Jiazhen Life Science Award from Fudan University, and the Prize for Important Innovation and Contribution from the Chinese Academy of Sciences.